NASDAQ:SABS - SAB Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: 20.00
  • Forecasted Upside: 90.48 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
10.50
▲ +1.6 (17.98%)

This chart shows the closing price for SABS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SAB Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SABS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SABS

Analyst Price Target is 20.00
▲ +90.48% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SAB Biotherapeutics in the last 3 months. The average price target is 20.00, with a high forecast of 23.00 and a low forecast of 17.00. The average price target represents a 90.48% upside from the last price of 10.50.

This chart shows the closing price for SABS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in SAB Biotherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/25/2021Robert W. BairdReiterated RatingBuy$23.00High
11/5/2021Chardan CapitalInitiated CoverageBuy$17.00Low
11/1/2021Robert W. BairdInitiated CoverageOutperform$23.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

SAB Biotherapeutics

Big Cypress Acquisition Corp. entered into a definitive business combination agreement with SAB Biotherapeutics Inc.
Read More

Today's Range

Now: 10.50
Low: 9.28
High: 10.75

50 Day Range

MA: N/A

52 Week Range

Now: 10.50
Low: 7.30
High: 12.90

Volume

774,968 shs

Average Volume

216,592 shs

Market Capitalization

$155.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of SAB Biotherapeutics?

The following equities research analysts have issued research reports on SAB Biotherapeutics in the last twelve months: Chardan Capital, and Robert W. Baird.
View the latest analyst ratings for SABS.

What is the current price target for SAB Biotherapeutics?

2 Wall Street analysts have set twelve-month price targets for SAB Biotherapeutics in the last year. Their average twelve-month price target is 20.00, suggesting a possible upside of 90.5%. Robert W. Baird has the highest price target set, predicting SABS will reach 23.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of 17.00 for SAB Biotherapeutics in the next year.
View the latest price targets for SABS.

What is the current consensus analyst rating for SAB Biotherapeutics?

SAB Biotherapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SABS will outperform the market and that investors should add to their positions of SAB Biotherapeutics.
View the latest ratings for SABS.

What other companies compete with SAB Biotherapeutics?

How do I contact SAB Biotherapeutics' investor relations team?

SAB Biotherapeutics' physical mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The company's listed phone number is 305-204-3338 and its investor relations email address is [email protected] The official website for SAB Biotherapeutics is www.bigcypressaccorp.com.